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Abstract
Cutaneous leishmaniases have persisted for centuries as chronically disfiguring parasitic infections 
affecting millions of people across the subtropics. Symptoms range from the more prevalent 
single, self-healing cutaneous lesion to a persistent, metastatic disease, where ulcerations and 
granulomatous nodules can affect multiple secondary sites of the skin and delicate facial mucosa, 
even sometimes diffusing throughout the cutaneous system as a papular rash. The basis for such 
diverse pathologies is multifactorial, ranging from parasite phylogeny to host immunocompetence 
and various environmental factors. Although complex, these pathologies often prey on weaknesses 
in the innate immune system and its pattern recognition receptors. This review explores the 
observed and potential associations among the multifactorial perpetrators of infectious metastasis 
and components of the innate immune system.
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An ancient and emerging disease
Leishmaniases have persisted for centuries as life-threatening and disfiguring parasitic 
diseases affecting millions of people across the subtropics. Currently, 98 countries are listed 
as having endemic disease, amounting to an estimated 12 million cases with 2 million more 
each year [1]. Human disease is caused by sp. of Leishmania protozoan parasites and is 
cycled among hosts through the bite of a female sand fly vector. Symptoms range from 
single self-healing cutaneous lesions to fatal visceralization or chronic metastatic 
dissemination throughout the skin. However, despite its prevalence, persistence, and 
conspicuous symptoms, the disease remains largely uncontrolled, with few new treatment 
options and no comprehensively effective vaccine. Migration and densification of 
populations in subtropical regions are compounding with global warming and a growing 
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HIV-positive (immunodeficient) demographic to class leishmaniasis as a serious emerging 
global threat [2]. Further, growing local and international instability has fuelled major 
outbreaks in new populations that spread quickly among the vulnerable of conflict zones, 
living in densely packed and poorly insulated shelters. These unsettled populations pose a 
risk of widening leishmanial geography during resettlement, as was the case after the 
Sudanese Civil War, the Gulf and Iraq wars, and currently among Syrian refugees [3,4].
The centuries of geographically isolated evolution have allowed each Leishmania spp. to 
develop intricate pathways of immune evasion, creating various symptomatic outcomes, and 
enabling parasites to persist under astounding immunological pressure, even existing as life-
long infections after symptomatic resolution [5].
A common route of entry – widely different outcomes
Leishmania is generally transmitted through the bite of an infected sand fly. However, from 
this common origin, the same sp. can cause widely different outcomes. In most instances, 
disease is ‘asymptomatic’, without any obvious pathology, although still able to support life-
long infection. The presence of persistent parasites in asymptomatic infections is a double-
edged sword – on the one hand, potentially conferring immunity to superinfection, but on 
the other hand, creating the dangerous likelihood of reactivation, which is often associated 
with a more severe symptomatic outcome. In infections for which pathology is overt, 
outcomes can again vary widely. Localized cutaneous leishmaniasis (LCL) occurs in many 
cases, which can persist as chronic open lesions or resolve into hyperpigmented scars. For 
the more severe forms of leishmaniasis, pathology is not limited to the infection site but 
instead progresses in various ways that can be divided into metastatic leishmaniasis, diffuse 
CL (DCL) or a systemic visceralization (VL) that has an important cutaneous complication, 
post-kala-azar dermal leishmaniasis (PKDL). These forms can also appear following 
seemingly ‘asymptomatic’ infections without a prior cutaneous presentation.
Surprisingly, little is known about the basic mechanisms of symptomatic divergence. This 
review aims to assemble the current knowledge on the immunological, environmental, and 
phylogenetic perpetrators of persistent and metastatic outcomes, which significantly 
complicate the diagnosis, treatment, and control of leishmaniasis. We also use this 
opportunity to propose new potential risk factors that are supported by anecdotal evidence 
with the hope to stimulate much-needed further research.
Symptomatic outcomes of cutaneous leishmaniasis
Human infections are generally caused by species of two major Leishmania subgenera, 
namely Leishmania (Leishmania) and L. (Viannia). Although L. (Leishmania) is found 
worldwide, the majority of infections occur in the Paleotropics (Eurasia and Africa), where 
common infecting species are Leishmania major, Leishmania tropica, Leishmania 
aethiopica, and Leishmania donovani. Species of the Viannia subgenus, by contrast, are 
exclusively endemic in the Neotropics (the Americas), with common infections being 
caused by Leishmania braziliensis, Leishmania panamensis, and Leishmania guyanensis. 
Depending on the infecting species and the immune response in a susceptible host, 
Leishmania parasites can induce two major pathologies: VL or CL.
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Although VL, or ‘kala-azar’ (see Glossary), is the most serious form of the disease, it is 
relatively rare, contributing to only 10% of all leishmaniasis worldwide. Leishmania 
parasites are mostly dermotropic, where even VL is often followed by the diffuse and 
difficult-to-treat cutaneous lesions of PKDL. This review focuses on the various forms of 
persistent CL.
Localized cutaneous leishmaniasis
CL is endemic in numerous regions of the subtropics. It is most frequently caused by L. 
major, L. tropica, and L. aethiopica in the Paleotropics, whereas in the Neotropics it is 
caused by Leishmania mexicana and Leishmania amazonensis, or L. (Viannia) braziliensis, 
L. (Viannia) panamensis, and L. (Viannia) guyanensis [6]. Although CL generally manifests 
as a lesion localized at the inoculation site (LCL), its various physical presentations and 
immunopathologies have complicated diagnosis and scuttled attempts of forming a universal 
therapeutic or vaccination strategy. Globally, lesions can vary from a small self-healing 
ulceration to granulomatous nodules and large, seeping, erythematous wounds. Chronic 
infection and inflammation can last for several months or years and often leads to significant 
tissue damage and permanent, hyperpigmented scarring. In certain cases, the infection 
metastasizes to sites beyond the inoculation and can be referred to as metastatic 
leishmaniasis, by analogy to tumor cell metastasis.
Metastatic leishmaniasis
Metastatic complications occur across all regions where leishmaniasis is endemic but are 
particularly prevalent and aggressive in L. (Viannia) infections of the Neotropics [7]. They 
may also present with various symptoms, seemingly dependent on differences in the 
immune response elicited by the various metastatic parasite species (Box 1). Particular 
symptomatic outcomes can be grouped geographically (Figure 1), where, for example, the 
Paleotropics hosts many forms of nonulcerative, papular, and herpetiform leishmaniasis 
spreading within a small radius of the primary lesion, whereas the Neotropics is better 
known for large ulcerative and granulomatous lesions, which often occur at sites distant 
from the primary lesion. Indeed, certain Neotropical parasites have a specific tropism for the 
delicate mucosal tissues of the nose and face, creating a particularly disfiguring disease 
known as mucosal leishmaniasis. The inflammation in the nasal mucosa is inordinately 
potent when contrasted with the sometimes undetectably low number of parasites. Lesion 
biopsies often reveal no infection. This phenomenon emphasizes the major role of the 
immune response in disease pathology and the potential of immunomodulatory agents in 
antileishmanial therapy. However, the immune involvement is diverse and opposing 
responses have been blamed for the various forms of infectious metastasis. For example, the 
mostly Paleotropical recidivans CL is described as a symptomatic reactivation of infection 
within the scars of a healed lesion; it is characterized by a potent cell mediated response in 
multiple nodules, which spread and coalesce to form significant tissue damage. Conversely, 
a total lack of a cell mediated response has been seen in DCL, where infection diffuses into 
hundreds of immunologically anergic nodules throughout the skin [8].
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Post-kala-azar dermal leishmaniasis
PKDL is an important dermal complication of Paleotropical VL, occurring in 10–20% of VL 
patients in India and up to 60% in Eastern African states such as Sudan and Ethiopia [9]. 
Although treatment is essential in Indian PKDL, African disease is generally self-healing. In 
most cases, patients feel otherwise well and present with a range of slowly evolving painless 
macular or papular rashes over large body surfaces, generally radiating from facial mucosa 
to large surfaces of the trunk and limbs. Nevertheless, the persistence of this seemingly 
harmless rash may play a more insidious role in the life cycle of its causative agent, L. 
donovani: functioning as a reservoir phase to shelter the parasite during the interseasonal 
periods of the sand fly. Indeed, the disease is mostly anthroponotic in these regions and only 
a few isolated studies have identified a potential animal reservoir. Despite the fact that the 
disease is caused by the same parasite, slight differences are seen between presentations in 
Africa and India. African PKDL patients have a higher tendency for ulcerative nodular 
forms, whereas Indian patients more commonly experience hypopigmented and 
maculopapular rashes with large plaque formations (Figure 1B). Interestingly, PKDL occurs 
almost exclusively in patients that were previously cured of VL and may appear up to 20 
years after the initial infection; the average inter VL–PKDL period is 6 years on the Indian 
subcontinent and less than 1 year in Africa [9]. Although PKDL in Sudan can appear 
concurrently with, or sometimes in the absence of, VL, in general the disease is highly 
uncommon in patients who have not yet presented with VL and received treatment. Thus, 
certain therapies are actually considered a significant risk factor for developing the disease 
[10]. Because the therapies often restore or boost the patient’s inflammatory T helper 1 
(Th1) immune response, PKDL is widely accepted as being an immunologically mediated 
disease (Box 2).
Importantly, the appearance of any one of these forms of leishmanial metastasis can occur 
several months or years of the initial infection and often appear after the resolution of the 
initial infection with seemingly no predictive factors. The next part of this review describes 
a few circumstantial risk factors that may identify patients at higher risk of developing 
metastatic disease.
Metastatic risk factors
The mechanisms behind metastatic potential are currently unknown. Although 
immunological and environmental vulnerabilities in the host and various parasite 
phylogenies have been linked to the onset of infectious metastasis (Figure 2), there is no 
consensus on which of these factors is essential. Conflicting evidence is probably an 
indication that the process is multifactorial and dependent on complex interactions among 
parasite, host, and environmental factors, including genetic and nongenetic factors.
Metastatic risk factors in the parasite
Phylogeny and polymorphisms
Geographical boundaries remain the clearest delineation among symptomatic outcomes, and 
because they parallel parasite-specific endemic regions, it is often assumed that disease 
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outcomes branch with parasite phylogeny. So far, comparative analysis across the genomes 
of LCL, metastatic CL, and VL Leishmania spp. has not revealed a universal ‘metastatic 
gene’ [11–13]. Nevertheless, these studies cannot yet include the effect of differential 
protein expression achieved through changes in gene regulation, copy number, single 
nucleotide polymorphisms, or the presence of pseudogenes [14]. Although many of the 
differentially expressed genes are ‘hypotheticals’ of unknown function, some may have 
putative virulence activity. For instance, metastatic L. braziliensis is known to carry 
supplementary copies of NADPH-dependent fumarate reductase and a homolog of 
glutathione peroxidase (as well as having lost a trypanothione synthase-like protein): all are 
important enzymes in the detoxification of oxidative stress. Whether these have any 
physiological importance is unknown. Hopefully, the rapidly growing database of 
Leishmania genomes (www.tritrypdb.org) will soon provide more insight into the role of 
parasite phylogeny in symptomatic outcome.
Although differences at the genetic level are poorly identified, various physiological 
differences have already been described, where metastatic parasites seem to have improved 
survival capabilities attributable to improved resistance to oxidative stress [15] and 
antileishmanial drugs such as antimony [16,17]. Interestingly, some studies have found 
heterogeneity among parasites isolated from the metastatic and primary lesions within the 
same patient. The most striking example was found in PKDL, where visceralizing parasites 
had significant genetic differences to those found later in the skin during PKDL [18,19]. 
Further, the cutaneous parasites showed an upregulation of certain surface proteins 
associated with virulence [20], implying that metastasis is a result of divergent parasite 
evolution or that, rather than metastasis, patients are actually reinfected with a variant, for 
which their existing immunity to previous infection acts as a susceptibility factor for the 
onset of PKDL.
Overall, findings support the hypothesis that infectious metastasis arises from low levels of 
persistent infection, where slowly dividing or ‘dormant’ parasites are possibly reactivated by 
antimony treatment or some similar type of immunological stress [16,17]. Indeed, parasites 
can often be detected in histologically ‘normal’ mucosal tissues of LCL patients [21], 
thereby indicating that this state of dormancy is probably achieved through a tightly 
controlled immunological tolerance rather than by transforming into a specialized ‘dormant’ 
morphology, for which there is no substantial evidence. Convincing support of immune 
tolerance is seen repeatedly where disruptions to immune functioning initiate symptomatic 
reactivations, such as after organ transplants or herpes zoster infection [22]. So far, some 
links to reactivation have been found in variations of parasite immunogenicity, where the 
concentration or combination of certain pattern recognition receptor (PRR) ligands is able to 
determine the course of infection. A striking example of this arises from a surprising 
nongenetic source, discussed below.
Nongenetic factors
We recently provided evidence that cytoplasmic pathogens of the Leishmania parasite can 
influence the course of leishmaniasis. Here, strains of L. guyanensis were found to be 
infected by a cytoplasmic virus, Leishmania RNA virus (LRV). These LRV-bearing 
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parasites repeatedly metastasized in a hamster model of infection, in contrast to their LRV-
negative counterparts [23,24]. The process was shown to be immunologically mediated, 
where the viral double-stranded RNA (dsRNA) provoked a potent inflammatory response 
after engaging endosomal Toll-like receptor 3 (TLR3), resulting in the production of 
interferon (IFN)-β, which inflamed and worsened leishmanial lesions in mice as well as 
prolonging parasite survival. This situation of improved parasite survival in spite of a potent 
inflammatory response is reminiscent of what is observed in human mucosal leishmaniasis 
patients. This variant of LRV (LRV1) has since been found in various isolates of 
Neotropical metastatic cutaneous leishmaniasis (MCL) from species of L. guyanensis and L. 
braziliensis [25]. Further, a depletion of LRV1 in genetically identical L. guyanensis clones 
confirmed the role of LRV1 in disease severity [23]. Similar to other Totiviruses, which are 
generally neither shed nor infectious and thus inherited only vertically or during genetic 
exchange, the relationships between the LRVs closely parallel the relationships between the 
parasite species within which they reside. Recently, confirmation of the presence in L. 
aethiopica of a new LRV variant of the single (and exceptional) LRV2 isolate of L. major 
[26], indicates that LRV infection may have a much wider global reach. As described in Box 
1, L. aethiopica is one of the few Paleotropical species causing metastatic complications 
such as mucosal leishmaniasis and DCL. So far, however, LRV has only been proven to act 
as a virulence factor in murine models of L. guyanensis infections. Its clinical role in L. 
braziliensis and L. aethiopica infections is yet to be defined. Unfortunately, no reliable 
clinical or epidemiological data exist to assess the correlation between LRV presence and 
metastatic leishmaniasis. Current reports show that infectious metastasis for L. braziliensis is 
not exclusively associated with LRV presence [27]. Additionally, LRV has not yet been 
detected in L. panamensis, which can also cause mucosal leishmaniasis. These facts suggest 
that infectious metastasis is a complex multifactorial process, in which the host and its 
environment also play a major role.
Metastatic risk factors in the host
Although fair assumptions can be made on host risk factors from approximations in animal 
models, the lack of large-scale or systematic human studies leaves many questions regarding 
the effect of human-specific or ‘real-life’ factors, such as risks stratified with socioeconomic 
status, ethnicity, genetics, or occupation. The lack of these studies are probably a major 
contributing factor to the conflicting data found in studies on leishmanial metastasis.
Immunology and environment
Leishmaniasis has established itself as an emerging opportunistic infection in HIV-positive 
patients, where its occurrence is now used as a clinical indicator for performing an HIV test. 
Indeed, HIV predisposes the onset of less common leishmanial complications such as VL 
and diffuse metastatic infection by 1000-fold [2]. Similarly, the immunological dysfunction 
associated with severe malnutrition can also be exploited by leishmaniasis and stands as the 
most prevalent cause of immunodeficiency worldwide [28]. Equally, metastatic leishmanial 
complications have been associated with sudden immune-reconstitution such as after highly 
active antiretroviral therapy (HAART) [29] or Th1-boosting antimonial therapy [30], thus 
showing that diverse fluctuations in immunocompetence can influence CL. As 
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immunocompetence also determines the composition of the host microbiome, a recent study 
has elegantly linked disruptions in skin commensals to the control of CL [31]. This study, 
however, did not investigate leishmanial metastasis, but we can postulate the potential 
importance of these potently immunomodulatory ‘co-infections’, especially considering the 
metastatic influence of the nested co-infection, LRV.
Local changes in skin immunity after physical injuries have already been shown to 
predispose metastatic reactivations. Here, secondary lesions were observed to develop in the 
scar tissue of unrelated wounds [32]: a phenomenon implying that, similar to cancer, 
metastatic sites are immunologically ‘seeded’ before the establishment of secondary lesions 
by local changes in the immune microenvironment. These local variations in immunological 
status remain as an interesting and underdeveloped avenue of study in leishmaniasis. The 
most common and potent facilitators for these local changes are the PRRs, which are at the 
frontline of innate pathogen recognition. Each PRR has an immunological arsenal specific to 
a range of signature pathogen ligands. Thus, concomitant infections stimulating a variety of 
PRRs induce a range of signaling cascades that not only blend together to create a unique 
immunological microenvironment but are also able to synergize or inhibit each other. 
Further, it has been shown that even a previous infection in the host can alter subsequent 
PRR activity, inducing homotolerance and heterotolerance or hyperactivity [33]. The potent 
effect of TLR3 signaling on disease severity, exemplified in the case of LRV nested co-
infection, sheds light on the possible importance of the number, timing, and magnitude of 
innate immune responses in the evolution of leishmaniasis. Consequently, the mechanism 
whereby HIV infection acts as an aggravating factor in metastatic leishmaniasis may be far 
more complex than a simple collapse of the CD4 compartment. Indeed, Leishmania survive 
better in cells exposed to HIV and vice versa [34,35]. This creates a situation where PRR 
crosstalk as well as genetic polymorphisms in these PRRs (Box 3) should be considered as 
key parameters of leishmanial pathogenesis.
Pattern recognition receptors and Leishmania
The Leishmania parasite has several molecular patterns, which are sensitively detected by 
the innate PRRs of the host. The host cell of the obligate intracellular stage of Leishmania is 
the macrophage, a potent immune phagocyte notoriously coated and lined with various 
PRRs, and so it is clear that the parasite does not go by undetected. Indeed, inoculation 
results in a rapid initiation of inflammatory signaling cascades, where the collateral tissue 
damage of the resultant hyperinflammation is at the root cause of disease pathology. Three 
major families of signaling PRRs have been identified: the TLRs, the nucleotide-binding 
domain, leucine-rich repeat containing receptors (NLRs), and the retinoic acid-inducible 
gene 1 like receptors (RLRs). So far, the TLRs are the most extensively described.
Toll-like receptors
In Leishmania infection, the role of certain TLRs has been well documented and recently 
reviewed [36,37]. In most instances, studies were based on the common adaptor molecule 
MyD88, where deficient mice showed that TLRs play a generally protective role against 
Leishmania infection. This MyD88-dependent protection was mostly attributed to TLR2 and 
TLR4 signaling that have been repeatedly noted as beneficial across a broad range of 
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Leishmania species [38–40]. Interestingly, however, the MyD88 pathway is not exclusive to 
TLRs, and thus these protective roles may also be explained by MyD88-dependent 
components of IL-1/IL-18 signaling, as will be discussed in the next section. Nevertheless, 
further protective roles were found for endosomal TLRs (sensing nucleic acids) through 
studies on the Unc93B1 chaperone protein: involved in the translocation of TLRs from the 
endoplasmic reticulum to endosomes [41]. Among the endosomal TLRs, TLR9 seems 
crucial to pathogenesis, because TLR9-deficient mice are rendered more susceptible to L. 
major [42,43], L. braziliensis [44], and L. guyanensis [45]. However, as mentioned 
previously, it is difficult to make generalizations about TLRs from these studies as 
Leishmania may engage multiple TLRs with intersecting pathways that are then able to 
either synergize with or reduce the efficacy of the co-stimulated pathway. For example, L. 
panamensis induces TLR1, TLR2, TLR3, TLR4, and TLR9 transcription in primary 
macrophages [46]. The TLR4 ligand in L. panamensis remains to be determined, however, 
as Viannia spp. lack the P-8 proteoglycolipid complex that is generally responsible for 
leishmanial TLR4 stimulation. Further, the classic TLR2 ligand, LPG, is also expressed in 
significantly lower quantities (10–20-fold less) in Viannia. It is possible that its activation 
and upregulation could be attributed to crosstalk, where nuclear factor-κB (NF-κB) 
activation, a common target of many PRRs, is known to upregulate TLR2.
Protection via TLRs is usually linked to the production of proinflammatory cytokines, such 
as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), C-X-C motif chemokine 10 
(CXCL10), and chemokine ligand 5 (CCL5). Importantly, however, these same 
immunological mediators of protection have also been blamed for the extreme inflammation 
associated with mucosal and metastatic leishmaniasis. The model of LRV-dependent 
metastasis is one such example where TNF-α-mediated hyperinflammation not only induces 
tissue damage that worsens disease outcome but is also favorable to parasite survival [47], 
indicating that the magnitude as well as the combination of TLR signaling is important in 
determining disease outcome [48]. Immunological crosstalk has already been described 
among many TLRs [33]. TLR7 stimulation, for instance, can induce inhibitory 
heterotolerance on concomitantly stimulated TLR2, TLR4, and TLR9 pathways [49]. 
Further, TLR3 has shown inflammatory synergy with TLR9 and TLR2 [50,51], a 
phenomenon that may account for the hyperinflammatory response seen in TLR3 
stimulatory Leishmania infections carrying LRV. These studies propose that TLR 
stimulation should be investigated in a multidimensional manner, taking into account not 
only the incidence of their stimulation but also the concomitantly stimulated receptors and 
the chronological order in which they are stimulated.
NLRs and RLRs
Unlike the TLRs, NLRs are exclusively intracellular, enabling stressed, damaged, or 
infected cells to directly sense and respond to internal danger signals. Although the signals 
and activation complexes are very different from those of the TLR pathway, some family 
members (NOD1 and NOD2) can directly engage the common TLR nuclear factor, NF-κB, 
producing many of the same proinflammatory cytokines. Most NLR family members, 
however, signal through the formation of an inflammasome, a multiprotein complex that 
induces inflammation via caspase-1-mediated cleavage and activation of pro-IL-1β and pro-
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IL-18 [52]. The RLRs, by contrast, detect foreign cytoplasmic DNA and RNA to induce an 
antiviral immune response. The RLRs include RIG-I and MDA5, which work via interferon 
regulatory factor 3 (IRF3) and IRF7 by utilizing the mitochondrion-localized adaptor protein 
MAVS [53].
Because NLRs and RLRs are able to detect both pathogen-associated molecular patterns 
(PAMPs) as well as cellular danger signals (which are undoubtedly present in the destructive 
inflammatory environment of a typical leishmanial lesion), we expect to find a significant 
role for NLRs and RLRs in the evolution of disease. Despite this great potential, however, 
studies on their involvement in leishmaniasis are sparse. Thus far, there is no report on a 
possible role of RLRs in leishmaniasis and only a handful on NLR activation. The first study 
describing the role of NLRs in leishmaniasis correlated the clearance of various New World 
Leishmania species to an NLRP3-dependent production of nitric oxide (NO) and IFN-γ [54]. 
The authors showed that the resultant active IL-1β induced by NLRP3 signaling carried out 
this response in an autocrine manner, where the IL-1 receptor and its MyD88 adaptor protein 
were necessary and sufficient to trigger inducible nitric oxide synthase (iNOS). 
Interestingly, immunological cross-talk from TLR4 can increase the inactive IL-1β 
precursor, thus facilitating the NLRP3 response by ‘priming the system’ [55]. Indeed, TLR4 
is an essential component of initiating parasitotoxic oxidative stress in L. major infection. 
Although these studies note NLRP3 inflammasome activation, they did not identify the 
stimulating ligand. In the ulcerative environment of a typical leishmanial lesion, we expect 
many cellular danger signals with the potential of NLRP3 stimulation. An example of such 
activation has been described, whereby nucleotides released by macrophages infected with 
L. amazonensis engaged the purinergic receptors (P2Y2 and P2Y4), often found upstream of 
the NLRP3 inflammasome. This drastically reduced parasite burden and even induced 
apoptosis of the host cell [56]. TLR crosstalk can also have a deleterious effect on this 
parasitotoxic inflammasome, for instance, IFN-β, such as is produced in response to TLR3 
engagement, is known to disrupt oxidative parasite killing via the upregulation of superoxide 
dismutase (SOD1) [57]. This molecule decreases caspase-1 activation, which is an essential 
part of NLRP3 inflammasome function [58]. SOD1 upregulation is seen particularly in 
Neotropical Leishmania spp., where infectious metastasis (and IFN-β inducing LRV1) is 
endemic. Interestingly, IFN-β is described as having many contradictory roles in 
leishmaniasis (Box 4).
The only other study on the inflammasome in leishmaniasis was a preliminary effort to 
profile the transcription of inflammasome components in a macrophage system of infection. 
Here, the authors quantified the mRNA of two inflammasomes (NLRP3 and NAIP5), as 
well as some common inflammasome adaptor/effector molecules (IPAF, ASC, caspase-1, 
IL-1β, and IL-18) in macrophages infected with L. major and found a significant 
upregulation for all the above-mentioned components except NAIP5 [59]. Again showing 
the potential for such studies in leishmaniasis. Anecdotal evidence widely supports a role for 
NLRs in leishmaniasis, for instance, a common NRLP3 stimulant, poly (lactic-co-glycolic) 
acid (PLGA), is an effective adjuvant in a KMP11-based antileishmaniasis vaccine [60].
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The virus-recognizing RLRs would probably have the highest potential to play a role in 
Leishmania infected with the dsRNA virus, LRV. However, it is also likely that the length 
of the dsRNA genome of LRV may not fit the size restrictions for RLR activation.
Concluding remarks
Infectious metastasis in CL is a complex, multifactorial process involving various risk 
factors. Much research is still needed to definitively identify the exact causes of this 
disfiguring complication and, further, to gauge their relative contributions in the 
pathogenesis of disease. Outstanding questions for further research are proposed in Box 5. 
So far, anecdotal evidence has short-listed some candidate ‘metastatic risk factors’ in 
parasite phylogeny, host immunocompetence, and environmental influences, which were 
summarized here. The geographical isolation of metastatic outcomes insinuates that parasite-
intrinsic factors are the overriding determinants of the complication. Indeed, metastatic 
parasites seem to have an increased resistance to oxidative stress and antileishmanials, 
prolonging their survival even in the more potently inflammatory environment that they tend 
to induce. Nevertheless, the small genetic differences between metastatic and nonmetastatic 
parasites make the presence of a ‘metastatic gene’ unlikely. This indicates that increased 
parasite survival is probably attributable to nongenetic factors or to a more complex 
situation of immune evasion in the host. A strong candidate for such a nongenetic, 
immunomodulatory metastatic factor is the presence of the highly immunogenic dsRNA 
virus within the cytoplasm of metastatic strains of L. braziliensis, L. guyanensis, and L. 
aethiopica parasites. This potently pathogenic role for an innate antiviral pathway strongly 
implicates PRRs and coinfecting pathogens in metastatic leishmaniasis. Already, 
encouraging studies have shown the substantial influence of the host skin microbiome and 
HIV viral particles in leishmanial lesion formation and parasite survival. Therefore, further 
studies on PRR polymorphisms and crosstalk in metastatic disease have great potential to 
reveal associations and ultimately stand as evidence for the use of innate immunomodulators 
in the treatment and prevention of metastatic disease.
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Glossary
Damage- (or 
Danger-) associated 
molecular patterns 
(DAMPs)
molecules that are generally present due to a noninfectious threat 
to cellular integrity and are capable of initiating signaling 
cascades, through PRRs such as NLRs and TLRs. Some 
examples are proteins released during DNA damage such as 
cytosolic DNA and RNA fragments, or nucleotides such as ATP. 
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Fragments of damaged tissue such as hyaluronan, uric acid, and 
heparin sulfate have also been described as potent DAMPs
Highly active 
antiretroviral 
therapy (HAART)
a combination of at least three drugs proven to suppress HIV 
replication, thus prolonging and improving the quality of life for 
individuals with HIV. A combination is used to avoid the 
development of drug resistance
Immune 
reconstitution 
inflammatory 
syndrome (IRIS)
a condition developing during immune recovery from a major 
immunosuppressive event (e.g., HIV infection, or VL) in which 
the immune system responds to previously acquired antigens 
with an overwhelming level of inflammation that paradoxically 
worsens the disease
Kala-azar (KA) a Hindi term for ‘Black Fever’, describing the unexplained 
cutaneous discoloration associated with end-stage VL, where 
parasites fatally (if left untreated) infest the liver, spleen, and 
bone marrow
Leishmania RNA 
virus (LRV)
a cytoplasmic double-stranded RNA (dsRNA) virus residing 
within some strains of the Leishmania parasite, which may act as 
a virulence factor in metastatic leishmaniasis
Nucleotide-binding 
oligomerization 
domain receptors 
(NLRs)
also called Nod-like receptors, are intracellular sensors of 
PAMPS and DAMPs able to cooperate with TLRs to regulate or 
potentiate the inflammatory and apoptotic response
Pathogen-associated 
molecular patterns 
(PAMPs)
small molecular motifs common among certain pathogen groups 
that are recognized by PRRs in cells of the innate immune 
system and generally produce a cytokine signaling cascade. 
Some examples include bacterial lipopolysaccharide (LPS, 
specific to TLR4), flagellin (TLR5), dsRNA (TLR3), and 
unmethylated CpG DNA (TLR9)
Retinoic acid-
inducible gene 1 like 
receptors (RLRs)
also called RIG-1-like receptors, are cytoplasmic RNA helicase 
enzymes, which recognize viruses by binding their dsRNA. 
RIG-1, MDA5, and LGP2 are the currently described members 
of this PRR family
T helper cell subsets 
(Th1/Th2/Th17/Treg)
subsets of a CD4 T cell lineage, which promote various types of 
immune response. Th1: cell mediated cytotoxic response (via 
IFN-γ). Th2: B cell mediated antibody response (via IL-4, IL-5, 
and IL-13). Th17: antifungal response (via IL-17A). Treg: anti-
inflammatory response (via IL-10)
Toll-like receptors 
(TLRs)
are PRRs able to detect a range of pathogenic patterns on the 
plasma membrane (TLR1, TLR2, TLR4, TLR5, and TLR6) or 
within the endosomal compartment (TLR3, TLR7/8, and TLR9)
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Box 1. Species-specific immunopathologies of metastatic leishmaniasis
L. braziliensis
Mucosal leishmaniasis is most frequently observed with L. braziliensis, where metastasis 
occurs in 5–10% of CL patients. Although the manifestations of this disease can be 
complex, mucosal leishmaniasis generally metastasizes directly to the nasal mucosa with 
a limited number of secondary skin lesions. It most commonly affects the nasal septum, 
although infections have also been noted in the cartilaginous turbinates as well as the 
larynx. Mucosal lesional biopsies commonly reveal an unregulated hyperinflammatory 
response, where proinflammatory cytokines such as IFN-γ and TNF-α are produced 
without the dampening influence of IL-10 and transforming growth factor-β (TGF-β) 
[61,62]. Patients also produce significant quantities of inflammatory chemokines 
(CXCL10 and CCL4), resulting in the recruitment of intralesional CD8+ T cells [39]. 
Recently, the cytotoxic enzymes (granzyme B and perforin) produced by these 
intralesional CD8+ T cells were shown to mediate tissue damage in ulcerative CL 
[63,64]. However, it is also likely that tissue destructive enzymes such as matrix 
metalloproteases play important roles, although knowledge on their specific actions in 
metastatic leishmanial pathologies is sparse [65–67].
L. panamensis
More rarely, mucosal leishmaniasis can be caused by L. panamensis, a species that is 
endemic in western South America (Bolivia, Peru, and Colombia) and has also been 
found in Brazil. In Colombia, L. panamensis causes 55–80% of CL cases, 5% of which 
progress into mucosal leishmaniasis. Mucosal lesions due to L. panamensis have a 
tendency to be less destructive and less severe than those induced by L. braziliensis. 
Immunopathology in L. panamensis infection consists of a mixed Th1/Th2 immune 
response with high numbers of T regulatory cells [68]. Elements of this observation were 
recently replicated in a BALB/c murine model, which also revealed IL-13 and IL-4Ra as 
mediators of parasite persistence [69].
L. guyanensis
The clinical picture is slightly different for L. guyanensis, which is possibly the most 
prevalent parasite species in the Amazon basin. Although mucosal leishmaniasis has been 
described for L. guyanensis, the more common presentation is a large number of 
secondary lesions, which are nonulcerated, granulomatous, and display a weak response 
to treatment [70]. In general, L. guyanensis are less sensitive to antimonials than L. 
braziliensis [17] and parasites isolated from secondary lesions are more resistant to 
oxidative stress [15]. The intralesional immune response involves a strong role for T 
regulatory cells, which have been shown to underlie the chronicity of infection [71].
L. aethiopica
In the highlands of Ethiopia, there is a high incidence of CL caused by L. aethiopica. 
Generally, the cutaneous lesions are able to self-heal but persistent infections commonly 
metastasize to other parts of the body. Two major clinical presentations have been 
described: mucocutaneous leishmaniasis and DCL. DCL patients are poor responders to 
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antimony treatment and are anergic to parasite antigens, whereas mucocutaneous patients 
develop chronic inflammation and are sensitively reactive to parasite antigens. These 
clinical presentations are independent of parasite genotype [72] but may still be 
dependent on extranuclear parasite factors such as LRV, which has recently been 
discovered in the region [26].
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Box 2. Species-specific immunopathologies of PKDL
Interestingly, the onset of PKDL is strongly associated with the successful treatment of 
VL in which the restoration of the patient’s antileishmanial immune response reduces the 
visceral parasite load and results in symptomatic resolution [30] (Figure I). Antimonial 
therapy carries a specific risk of developing PKDL. However, cases have also been 
reported after treatment with amphotericin B and miltefosine [73]. Although the sudden 
shift from a Th2 response during VL to Th1 after treatment has been implicated in 
numerous studies, specifically being seen through the restoration of leishmanin skin test 
(LST) positivity [29], the mechanism seems to rely on a more complex underlying 
immune response. Indeed, high serum IL-10 and upregulated intralesional IL-6 and TNF-
α are predictive of, and essential to, the development of PKDL [9]. These high levels of 
local inflammatory markers could be compensatory for the malfunctioning IFN-γ 
signaling pathway, because although intralesional IFN-γ levels are high, its signaling 
seems to be corrupted by the low expression of the IFN-γ receptor [74]. The first line 
antileishmanials used for VL are known to induce or rather restore such cytokine 
environments and may thus explain the association of antileishmanial therapy to the onset 
of PKDL. Indeed, PKDL has recently been recognized as a form of paradoxical IRIS that 
emerges as a new disease entity following successful VL treatment and immune recovery 
[29].
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Box 3. Host PRR polymorphisms – a potential risk factor in metastatic 
leishmaniasis
PRRs have been almost completely overlooked in studies relating genetic polymorphisms 
to symptomatic variants of leishmaniasis. For instance, there is no study yet correlating 
PRR polymorphisms and susceptibility or resistance to Leishmania infection, although it 
is likely to be a key parameter in the control of parasite burden. Various genetic 
polymorphisms, however, have revealed immune susceptibilities for cytokines and 
chemokines in the pathology of metastatic leishmaniasis [75–79,88]. A few potential 
candidates are suggested below.
TLR polymorphisms
Numerous TLR polymorphisms have already been identified in humans and associated 
with the development of various common inflammatory diseases [89]. In the context of 
LRV recognition, TLR3 polymorphisms could play a major role in leishmanial 
metastasis. Several polymorphisms of TLR3 have been associated with human disease 
[80,90,91]. For instance, an intronic polymorphism, elevating TLR3 expression, was 
correlated with improved viral clearance in hepatitis C [92]. TLR3 polymorphisms have 
been similarly linked to common coinfections of leishmaniasis. For example, natural 
resistance to HIV-1 was associated with a common polymorphism (Leu412Phe) of 
TLR3, where the presence of the 412Phe allele was further associated with increased 
production of inflammatory cytokines [93]. Interestingly, the distribution of this allele 
varies between Eurasia and Africa, being almost absent in the latter group [94].
NLR polymorphisms
NLRs have also been associated with several diseases. For example, NLRP3, was 
originally named Cryopyrin for its association with a class of inflammatory diseases 
induced by low temperatures. Since then, similar pathologies have been mapped to this 
gene and are now commonly known as the Cryopyrin-associated periodic syndromes. 
Symptoms are mediated by hyperactive NLRP3 and a resultantly high level of the 
proinflammatory cytokine IL-1β. Surprisingly, loss-of-function polymorphisms have also 
been associated with chronic inflammatory conditions. An example of which is 
genetically defective NLRC2 expression, now strongly associated with Crohn’s disease 
[95,96]. This, however, could be explained by the fact that NLRC2 is essential in 
controlling gut bacteria through its recognition of a component of bacterial cell wall, 
muramyl dipeptide [97]. This reduction in microbial control could subsequently drive the 
inflammation associated with the development of Crohn’s disease. Because NLRC2 is 
especially expressed in the skin, this polymorphism results in a similar environment of 
proinflammation through disruptions of the cutaneous microbiome, and thereby 
influences the local inflammatory microenvironment in leishmaniasis. Therefore, much 
potential lies in the study of PRR polymorphisms in leishmanial pathogenesis.
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Box 4. The contradictory roles of IFN-β in leishmaniasis
Type I interferons, such as IFN-β, were originally discovered and defined by their ability 
to ‘interfere’ with viral infections and, for a long time, it was the sole function to which 
they were attributed. In recent years, more diverse roles have been added, ranging from 
antineoplastic agents to regulators of the immune system. They are currently found to 
have various and sometimes contradictory roles in viral, bacterial, and protozoan 
infections [98,99]. For leishmaniasis, the roles of IFN-β seem to be particularly 
conflicting, where IFN-β treatment has been demonstrated to play both protective and 
detrimental roles during L. major infection by differentially modulating iNOS expression, 
depending on the dose and timing of its administration [100]. For example, low-dose 
IFN-β treatment in a murine model was noted as having a significantly protective effect 
against progressive CL, restoring natural killer cell cytotoxic activity, increasing 
lymphocyte proliferation, and upregulating parasitotoxic nitric oxide [101]. However, 
high concentrations of this proinflammatory cytokine increased L. braziliensis parasite 
load and worsened disease in a murine model of L. amazonensis infection: an observation 
analogous to the correlation of hyperinflammation with increased parasite infectivity in 
metastatic disease. Parasites evidently benefited from an IFN-β-mediated upregulation of 
superoxide dismutase in human macrophages, thereby detoxifying the oxidative radicals 
used to kill intracellular infections [57], whereas destructive inflammation was caused by 
an extreme recruitment of inflammatory monocytes [102].
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Box 5. Outstanding questions
• Large-scale epidemiological studies are needed to understand the geographical 
extent and clinical relevance of the LRV nested coinfection in various 
Leishmania species.
• A continued and more robust search for parasite-intrinsic metastatic factors 
could be achieved through broad-ranging comparative studies at the genetic and 
protein levels.
• Genome-wide association studies on parasites and on leishmaniasis endemic 
human populations could reveal any immunological susceptibilities, which 
predispose leishmanial metastasis.
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Figure 1. 
Geographical context of the various outcomes of metastatic leishmaniasis. Metastatic 
cutaneous leishmaniasis (MCL) occurs across all Leishmania endemic regions but is much 
more prevalent in the Neotropics (A). Neotropical infections are mostly caused by the 
variously ‘metastatic’ species of the Leishmania (Viannia) subgenus. Species with high 
metastatic potential cause some form of MCL in approximately 20% of their infections. 
Neotropical MCL has a particular predilection for facial mucosa (1a–c) and are known for 
forming large ulcerative lesions (4–5) or, less frequently, diffuse granulomatous disease (2–
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3). The Paleotropics (B) have a much lower incidence of classic MCL. Post-kala-azar 
dermal leishmaniasis (PKDL), however, can occur in as many as 60% of all infections. MCL 
presentations vary from diffuse papular infections (6) to the rare leishmaniasis recidivans 
(12). PKDL presentations differ slightly between Eurasia and Africa, where India sees more 
progressive hypopigmented and macular rashes (11), whereas African PKDL has higher 
incidences of self-healing papular and ulcerative forms (9). All figures were kindly provided 
by Dr Philippe Desjeux. Geographically representative images were chosen from a global 
photographic catalog depicting the various symptomatic outcomes of cutaneous 
leishmaniasis.
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Figure 2. 
The potential risk factors of metastatic leishmaniasis. A summary of the anecdotal or direct 
evidence for risk factors that may predispose metastatic complications in cutaneous 
leishmaniasis [11–17,23,25,26,28,31,35,47,48,75–87].
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Figure I. 
The clinical context of post-kala-azar dermal leishmaniasis (PKDL) development. Visceral 
leishmaniasis (VL) is marked by high visceral parasite loads and is often associated with a 
weak or negative result for the leishmanin skin test (LST). The absence of LST reactivity is 
indicative of low cellular immunity against leishmanial antigens. VL is often successfully 
treated with antimonials resulting in a reduction of parasite load and recuperation of 
antileishmanial response. This stage of disease resolution is often where PKDL is initiated. 
PKDL develops in three clinically relevant stages, spreading as a hypopigmented rash from 
the periorificial regions of the face to the periphery as a maculopapular or ulcerative rash.
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